Abstracts tagged "pregnancy"

Abstract Number: 1571 • ACR Convergence 2023
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
Nurul Aulia Zakaria¹, Andrew Porter², Robert Maughan², Charis Pericleous², Japna Satara³, Matthew Colquhoun⁴, Priyanka Agrawal³, jan Nouza³, Harold Wilson-Morkeh³, Taryn Youngstein² and Justin Mason², ¹National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, ²National Heart & Lung Institute, Imperial College London, London, United Kingdom, ³Rheumatology, Hammersmith Hospital, London, United Kingdom, ⁴Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
Abstract Number: 0464 • ACR Convergence 2023
Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine
Lauren Tesoriero¹, Jennifer Kidd¹, Julie Piccione¹, Izmirly peter², Meredith Akerman¹, Steven Carsons¹, Patricia Rekawek¹ and Julie Nusbaum¹, ¹NYU Long Island School of Medicine, Mineola, NY, ²NYU, New York, NY
Background/Purpose: Outside of the known association of Ro antibody with congenital heart block (CHB), little is known about adverse maternal outcomes, and even less about…
Abstract Number: 0986 • ACR Convergence 2023
Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea
Yeo-Jin Song¹, Soo-Kyung Cho¹, Yu-Seon Jung², Jihyun Keum³, Sun-Young Jung², Dae Hyun Yoo⁴ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²College of Pharmacy, Chung-Ang University, Seoul, South Korea, ³Department of Obstetrics and Gynecology, College of Medicine, Hanyang University, Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: As female patients constitute a significant proportion of rheumatoid arthritis (RA) cases, pregnancy management is crucial for women with RA. This study aimed to…
Abstract Number: 1681 • ACR Convergence 2023
Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Eri Soga², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Tama, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Tacrolimus is one of the major treatment options of systemic lupus erythematosus (SLE) and is thought to be pregnancy compatible medication. Since little is…
Abstract Number: 0466 • ACR Convergence 2023
Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study
Marie Hornez¹, Anna Molto², Maxime Leroy³, beatrice banneville⁴, Rakiba Belkhir⁵, elodie chauvet⁶, Marion Couderc⁷, Emanuelle Dernis⁸, sandra Desouches⁹, Valerie Devauchelle¹⁰, Aline Frazier-Mironer¹¹, Laure Gossec¹², elisabeth Gervais¹³, Hubert Marotte¹⁴, Christophe Richez¹⁵, Jeremie SELLAM¹⁶, Raphaele Seror¹⁷, Véronique Le Guern¹⁸, Gaelle Guettrot-Imbert¹⁸, Nathalie Costedoat-Chalumeau¹⁹, Rene-Marc Flipo²⁰ and Jean-Guillaume Letarouilly²¹, ¹University of Lille, Lille, France, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³CHU Lille - Department of Biostatistics, Lille, France, ⁴Sorbonne universite and Pitié Salpêtrière Hospital, la Garenne Colombes, France, ⁵Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, ⁶CH Perpignan, Perpignan, France, ⁷CHU Gabriel Montpied, Clermont Ferrand, France, ⁸CH Le Mans, Le Mans, France, ⁹Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁰UBO, Brest, France, ¹¹APHP Lariboisiere Hospital, Paris, France, ¹²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ¹³CHU Poitiers, Poitiers, France, ¹⁴CHU Saint-Etienne, Saint-Etienne, France, ¹⁵Université de Bordeaux, Bordeaux, France, ¹⁶Sorbonne Université APHP, Paris, France, ¹⁷University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ¹⁸APHP Hôpital Cochin, Paris, France, ¹⁹Inserm DR Paris 5, Paris, France, ²⁰La Lettre du Rhumatologue, Paris, France, ²¹CHU Lille, Lille, France
Background/Purpose: There are limited data on the impact of the postpartum period (PP) on the activity of inflammatory rheumatic disorders (IRD), and the data available…
Abstract Number: 1003 • ACR Convergence 2023
A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis
Griffin Reed¹, Joyce Mathew¹, Kelsey Rigby², Mery Deeb³, Elena Cravens¹, Anthony Reginato⁴, Gofran Tarabulsi⁵ and Joanne Cunha⁶, ¹Brown University, Providence, RI, ²Dartmouth Hitchcock Medical Center, Falmouth, MA, ³Brown University, Warwick, RI, ⁴The Warren Alpert Medical School of Brown University, Providence, RI, ⁵Women and Infants Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁶The Warren Alpert Medical School of Brown University, Riverside, RI
Background/Purpose: Rheumatic disorders frequently affect women of childbearing age. These diseases and medications used to treat them can have adverse effects on fertility and fetuses.…
Abstract Number: 1682 • ACR Convergence 2023
Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block
Bettina Cuneo¹, Mala Masson², Colin Phoon³, Ashley Roman³, Peter Izmirly⁴, Amit Saxena⁵, Michael Belmont⁶, Christina Penfield³, Young Mi Lee³, Julie Nusbaum⁷, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Abuhamad¹⁰, Majd Makhoul¹¹, Gary Satou¹², Whitnee Hogan¹³, Nelangi Pinto¹³, Anita Moon-Grady¹⁴, Lisa Howley¹⁵, Mary Donofrio¹⁶, Anita Krishnan¹⁶, Homa Ahmadzia¹⁷, Stephanie Levasseur¹⁸, Erin Paul¹⁹, Sonal Owens²⁰, Kristopher Cumberback²¹, Jyothi Matta²², Gary Joffe²³, Christopher Lindblade²⁴, Andrew Rubenstein²⁵, Caitlin Haxel²⁶, Katherine Kohari²⁷, Joshua Copel²⁷, James Strainic²⁸, Tam Doan²⁹, Karla Bermudez-Wagner²⁹, Shreya Sheth²⁹, Stacy Killen³⁰, Theresa Tacy³¹, Michelle Kaplinski³¹, Lisa Hornberger³², Nicola Fraser³, Robert Clancy³ and Jill Buyon³³, ¹University of Colorado, Denver, Denver, CO, ²New York University, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Langone, New York, NY, ⁶New York University Langone Medical Center, New York, NY, ⁷NYU Long Island School of Medicine, Mineola, NY, ⁸Children's Heart Center, Las Vegas, NV, ⁹East Virginia Medical School, East Virginia Medical School, VA, ¹⁰East Virginia Medical School, Norfolk, VA, ¹¹Atrium Health Levine Children's Hospital, Charlotte, NC, ¹²University of California Los Angeles, Los Angeles, CA, ¹³University of Utah, Salt Lake City, UT, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁶Children's National Hospital, Washington, DC, ¹⁷George Washington University, Washington, DC, ¹⁸Columbia University, New York, NY, ¹⁹Mount Sinai, New York, NY, ²⁰University of Michigan, Ann Arbor, MI, ²¹University of Kentucky, Lexington, KY, ²²University of Louisville, Louisville, KY, ²³Perinatal Associates of New Mexico, Albuquerque, NM, ²⁴Phoenix Children's Hospital, Phoenix, AZ, ²⁵Dignity Health, Phoenix, AZ, ²⁶University of Vermont Children's Hospital, Burlington, VT, ²⁷Yale University, New Haven, CT, ²⁸UH Rainbow Babies, Cleveland, OH, ²⁹Baylor School of Medicine, Houston, TX, ³⁰Vanderbilt University, Nashville, TN, ³¹Stanford University, Stanford, CA, ³²Stollery Children's Hospital, Edmonton, AB, Canada, ³³Department of Medicine, NYU Grossman School of Medicine, New York, NY
Background/Purpose: The management of fetuses exposed to maternal anti-SSA/Ro autoantibodies is challenging as the clinician weighs the rarity of fetal atrioventricular block (AVB) against the…
Abstract Number: 0467 • ACR Convergence 2023
Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome
Rashmi Dhital, Rebecca Baer and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Autoimmune rheumatic diseases (ARD) and antiphospholipid syndrome (APS) are autoimmune conditions with increased risks of cardiovascular complications as well as negative pregnancy consequences. We…
Abstract Number: 1345 • ACR Convergence 2023
Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Michelle Ann Caesar, Diana Johnson, Kenneth Lyons Jones and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Abatacept is approved for the treatment of moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis. However, there are limited data on the safety…
Abstract Number: 1683 • ACR Convergence 2023
Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO
Megan Clowse¹, Teresa Swezey², Jerome (Jeff) Federspiel², Catherine Sims², Amanda Snyderman², Amy Corneli², Sarahn Wheeler² and JoAnn Zell³, ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³University of Colorado Anschutz Medical Campus, Denver, CO
Background/Purpose: Project ECHO™ in an education model that links experts with community providers through a series of video teleconferences. Each conference involves a brief didactic…
Abstract Number: 0468 • ACR Convergence 2023
Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes
Heejo Keum¹, Bonnie Bermas², Shivani Patel¹, Benjamin Chong¹ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Increased rates of adverse pregnancy outcomes (APOs) have been reported in association with rheumatologic diseases such as systemic lupus erythematosus (SLE), dermatomyositis (DM), and…
Abstract Number: 1347 • ACR Convergence 2023
Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination
Hiromi Shimada¹, Risa Wakiya², Shusaku Nakashima², Taichi Miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Rina Mino⁶, Mao Mizusaki², Kanako Chujo⁷, Ryoko Kagawa⁴, Hayamasa Yamaguchi⁴, Tomohiro Kameda² and Hiroaki Dobashi², ¹Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: It is important to control disease activity during pregnancy in women with rheumatic diseases because its exacerbation is associated with increased adverse pregnancy outcomes.…
Abstract Number: 1684 • ACR Convergence 2023
The Impact of Pregnancy Timing on Outcomes in SLE
Catherine Sims¹, Amanda Eudy², Ceshae Harding¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: To minimize risk of poor pregnancy outcomes, the ACR Reproductive Health Guideline recommends women conceive when SLE is well controlled and treated with pregnancy-compatible…
Abstract Number: 0469 • ACR Convergence 2023
Hydroxychloroquine and Preeclampsia Risk in Lupus Pregnancy: Results from a Large Regional Integrated Health Network
Julia Simard¹, Emily Liu², Amadeia Rector³, Miranda Cantu⁴, Daniel Kuo⁵, Eliza Chakravarty⁶, Maurice Druzin⁷, Gary Shaw⁷, Michael Weisman⁸ and Monique Hedderson², ¹Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Stanford University, San Francisco, CA, ⁴Global Lupus Support Group, Portage, MI, ⁵Kaiser Permanente, Redwood City, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Stanford University, Stanford, CA, ⁸Stanford, Los Angeles, CA
Background/Purpose: Pregnancies in patients with systemic lupus erythematosus (SLE) are at greater risk of preeclampsia. Hydroxychloroquine (HCQ) is recommended during SLE pregnancy to control disease…
Abstract Number: 1348 • ACR Convergence 2023
Reproductive Outcomes for Women with Vasculitis
Catherine Sims¹, Christine Yeung², Heather Tam³, Joyce Kullman⁴, Amanda Eudy⁵, Renee Borchin⁶, Cristina Burroughs⁶, Megan Clowse⁷ and Peter Merkel², ¹Duke University School of Medicine, Durham, NC, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Patient Powered Research Network, Stanford, CA, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Duke University, Raleigh, NC, ⁶University of South Florida, Tampa, FL, ⁷Duke University, Chapel Hill, NC
Background/Purpose: There are limited data on the reproductive health of women with vasculitis. This study utilized a large, prospective, international vasculitis pregnancy registry to survey…

« Previous Page
1
…
3
4
5
6
7
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].